drugset / Trial / NCT05000684
Study of JS004 Combined With Toripalimab for Advanced Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label phase I/II study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of JS004 injection combined with toripalimab in patients with advanced lung cancer who have failed standard therapy.
Timeline
- Start
- 2021-08-27
- Primary completion
- 2024-10-31
- Completion
- 2024-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tifcemalimab | Monoclonal antibody | 200 mg | — |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | — |